Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.68 USD
Change Today +0.01 / 0.18%
Volume 267.9K
ARWR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
Frankfurt
As of 11:30 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

arrowhead research corp (ARWR) Snapshot

Open
$5.64
Previous Close
$5.67
Day High
$5.79
Day Low
$5.61
52 Week High
09/9/14 - $17.42
52 Week Low
08/24/15 - $4.35
Market Cap
338.0M
Average Volume 10 Days
1.2M
EPS TTM
$-1.48
Shares Outstanding
59.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARROWHEAD RESEARCH CORP (ARWR)

Related News

No related news articles were found.

arrowhead research corp (ARWR) Related Businessweek News

No Related Businessweek News Found

arrowhead research corp (ARWR) Details

Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology include Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types. The company is also involved in the development of Adipotide, which is in phase I clinical trial for the treatment of obesity and metabolic disorders; and CRLX-101 that is in phase II clinical trial to treat various cancer types, including relapsed renal cell carcinoma, relapsed ovarian cancer, and non-metastatic rectal cancer. It has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates. The company was formerly known as InterActive Group, Inc. Arrowhead Research Corporation was incorporated in 1989 and is headquartered in Pasadena, California.

81 Employees
Last Reported Date: 11/25/14
Founded in 1989

arrowhead research corp (ARWR) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $543.6K
Chief Financial Officer
Total Annual Compensation: $293.4K
Chief Operating Officer
Total Annual Compensation: $384.2K
Vice President of Strategy & Program Manageme...
Total Annual Compensation: $222.8K
Chief Scientific Officer
Total Annual Compensation: $226.4K
Compensation as of Fiscal Year 2014.

arrowhead research corp (ARWR) Key Developments

Arrowhead Research Corp. Presents at Jefferies 2015 Hepatitis B Summit, Aug-06-2015

Arrowhead Research Corp. Presents at Jefferies 2015 Hepatitis B Summit, Aug-06-2015 . Venue: Boston Harbor Hotel, North Atlantic Room, Boston, Massachusetts, United States. Speakers: Bruce D. Given, Chief Operating Officer.

Arrowhead Research Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015

Arrowhead Research Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, the company reported revenue of $123,750 against $43,750 a year ago. Operating loss was $15,993,706 against $12,700,100 a year ago. Net loss was $15,936,053 against $11,626,451 a year ago. Loss per basic and diluted share was $0.27 against $0.22 a year ago. Net cash used in operating activities during the third fiscal quarter was $13.1 million compared with $9.8 million in the prior year period. For the nine months, the company reported revenue of $338,250 against $131,250 a year ago. Operating loss was $70,744,144 against $30,921,978 a year ago. Net loss was $67,197,746 against $36,294,880 a year ago. Loss per basic and diluted share was $1.19 against $0.81 a year ago.

Arrowhead Research Corp. to Report Q3, 2015 Results on Aug 04, 2015

Arrowhead Research Corp. announced that they will report Q3, 2015 results at 4:30 PM, Eastern Daylight on Aug 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARWR:US $5.68 USD +0.01

ARWR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARWR.
View Industry Companies
 

Industry Analysis

ARWR

Industry Average

Valuation ARWR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 861.2x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 571.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARROWHEAD RESEARCH CORP, please visit www.arrowheadresearch.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.